Fig. 1



Tumor volume; Median and Inter Quartile Range; n=10
Vehicle (PBS); i.p.
B-HH6-B-KV1 GE; 1 mg/kg i.v.; Day 22, 29
Rituximab; 1 mg/kg i.v.; Day 22, 29
Fludarabine 40 mg/kg i.p.; Day 22, 23, 24, 25
B-HH6-B-KV1 GE; 1 mg/kg i.v.; Day 22, 29
Fludarabine 40 mg/kg i.p.; Day 22, 23, 24, 25
Rituximab; 1 mg/kg i.v.; Day 22, 29
Fludarabine 40 mg/kg i.p.; Day 22, 23, 24, 25
Tumor volume (mm³)
3500.0
3000.0
2500.0
2000.0
1500.0
1000.0
500.0
0.0
20
22
24
26
28
30
32
34
36
38
40
42
44
Day after tumor cell inoculation

Fig. 2



Cell death induction after combination of B-HH6-B-KV1 GE and Fludarabine in Rec1 MCL cells
untreated
B-HH6-B-KV1 GE
Fludarabine
B-HH6-B-KV1 GE + Fludarabine
% viable cells (mean + SD)
120
100
80
60
40
20
0
0 h
24 h
48 h
72 h
time

Fig. 3



Cell death induction after combination of B-HH6-B-KV1 GE and Fludarabine in Z138 MCL cells
untreated
B-HH6-B-KV1 GE
Fludarabine
B-HH6-B-KV1 GE + Fludarabine
% viable cells (mean + SD)
120
100
80
60
40
20
0
0 h
24 h
48 h
72 h
time

Fig. 4




Cell death induction after combination of B-HH6-B-KV1 GE and Mitoxantrone in Granta-519 MCL cells
untreated
B-HH6-B-KV1 GE
Mitoxantrone
B-HH6-B-KV1 GE + Mitoxantrone
% viable cells (mean + SD)
120
100
80
60
40
20
0
0 h
24 h
48 h
72 h
time

Fig. 5


Cell death induction after combination of B-HH6-B-KV1 GE and Mitoxantrone in Rec-1 MCL cells
untreated
B-HH6-B-KV1 GE
Mitoxantrone
B-HH6-B-KV1 GE + Mitoxantrone
% viable cells (mean + SD)
120
100
80
60
40
20
0
0 h
24 h
48 h
72 h
time